Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT00504738 Completed - Asthma Clinical Trials

Lung Disease Collection (Qatar): Evaluation of the Lungs of Individuals With Lung Disease

Q-LD
Start date: April 2006
Phase: N/A
Study type: Observational

The purpose of this protocol is to obtain biologic samples from the blood and lungs from patients with lung diseases in order to study the causes and indications of these disorders, learn how these lung disease manifest and progress, and how the lung disease can be treated.

NCT ID: NCT00504439 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects

Start date: June 4, 2007
Phase: Phase 1
Study type: Interventional

To assess safety of SB-656933 following repeat dosing for 14 days.

NCT ID: NCT00504361 Completed - Asthma Clinical Trials

Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)

Q-BC
Start date: May 2006
Phase: N/A
Study type: Observational

This is a research study where researchers are collecting blood to evaluate the genetic characteristics of individuals with chronic lung diseases, including asthma, COPD (chronic obstructive pulmonary disease), interstitial lung disease, cystic fibrosis, and lung cancer. The investigators hope to be able to identify an association between a genetic make-up in the blood samples and the risks of developing a particular lung disease, or severity of a lung disease. The findings of this study might be important to develop future preventative methods and potential treatments for the management of lung disease.

NCT ID: NCT00501852 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of glycopyrronium bromide (NVA237) in patients with stable COPD, in comparison to an active comparator.

NCT ID: NCT00500864 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Magnesium Loading in Chronic Obstructive Pulmonary Disease

Start date: August 2004
Phase: Phase 1/Phase 2
Study type: Interventional

Dietary magnesium (Mg) intake has been shown to be independently related to lung function, airway reactivity, and respiratory symptoms in the general population. Inhaled Mg and IV Mg administration have been shown to promote bronchodilation and to improve lung function in asthmatic patients. Some studies have suggested that COPD patients exhibit decreased body levels of Mg. The purpose of the present study was to investigate the effects of acute IV Mg loading on parameters of respiratory function and maximal exercise capacity of stable COPD patients.The study hypothesis is that Mg administration will be associated to improvements on airflow and vasodilation leading to improvements of pulmonary function and exercise performance.

NCT ID: NCT00500526 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Effects of Singing in Chronic Obstructive Pulmonary Disease

Start date: January 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the effects of the practice of singing for a long period of time on pulmonary function data, quality of life, and dyspnea sensation of patients with COPD in stable clinical conditions. As singing is a type of respiratory training, the study hypothesis is that singing would improve maximal respiratory pressures, dyspnea sensation, and overall quality of life of these patients.

NCT ID: NCT00500461 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705

Start date: June 4, 2007
Phase: Phase 1
Study type: Interventional

GSK233705 is being developed for the treatment of chronic obstructive pulmonary disease. This will be an open-label, dose-ascending study in 7 healthy male subjects to establish well tolerated intravenous doses and an oral dose of GSK233705. The main objective of the study is to confirm an IV and oral dose for a definitive human radiolabel metabolic study.

NCT ID: NCT00500318 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Start date: July 2007
Phase: Phase 3
Study type: Interventional

This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.

NCT ID: NCT00496470 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease, COPD

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Start date: May 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.

NCT ID: NCT00495586 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease

TRANCE
Start date: October 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effectiveness of antibiotic therapy for patients with acute exacerbations of mild-to-moderate chronic obstructive pulmonary disease.